© Globe Newswire
08.01.2026
BBNX
LISTED
NASDAQ
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
News Preview
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
PCRX
LISTED
NASDAQ
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
News Preview
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, tod...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
LLY
LISTED
NYSE
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
News Preview
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and Zepbound compared to Taltz monotherapy In a key secondary endpoint, use of Taltz and Zepbound delivered a 64% relative increase in the proportion of p...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
08.01.2026
AGL
LISTED
NYSE
agilon health, inc. (AGL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AGILON HEALTH, INC. (AGL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
08.01.2026
AGL
LISTED
NYSE
Securities Fraud Investigation Into agilon health, inc. (AGL) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON AGILON HEALTH, INC. (AGL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
TLX
LISTED
NASDAQ
Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclus...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.01.2026
SKNY
LISTED
CSE
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
News Preview
VANCOUVER, BC / ACCESS Newswire / January 8, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a services agreement ("R&D Agreement") with Neuland Laboratories Limited ("Neuland Labs"), a global...
Themefolio
Profiler
Peergroup
© ActuNews
08.01.2026
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma announces the publication of its letter to shareholders
News Preview
Lyon, France – January 8, 2025, 6:00 PM CET – THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to shareholders.
To download the newsletter, click here.
This letter is also available on the Theranexus website (link), in the Shar...
Themefolio
Profiler
Peergroup
© ActuNews
08.01.2026
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma annonce la publication de sa lettre aux actionnaires
News Preview
Lyon, France – 8 janvier 2026, 18h CET – THX Pharma (Theranexus), société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, annonce ce jour la publication de sa lettre aux actionnaires.
Pour télécharger la newsletter, cliquez ici
Cette lettre est également consultable sur...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
INKT
LISTED
NASDAQ
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
News Preview
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the upcoming initiation of a Phase 1, investigator-sponsored clinical trial evaluating its lead therapy, agenT-797...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
45030
LISTED
XJPX
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
News Preview
Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored Effective management of adverse events re...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
ALK B
LISTED
CPH
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
News Preview
ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
08.01.2026
DGX
LISTED
NYSE
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
News Preview
SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results begin...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
ALXO
LISTED
NASDAQ
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VNRX
LISTED
XASE
VolitionRx Secures $2.0 Million in Funding
News Preview
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind Global Asset Management XII LLC (the "Investor"), an investmen...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VTRS
LISTED
NASDAQ
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
News Preview
PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also st...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
KZIA
LISTED
NASDAQ
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
News Preview
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week).
During the week, Kazia will connect with existing and prospective institutional...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
ELVN
LISTED
NASDAQ
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
News Preview
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohortsELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels evaluated, consistent with previously reported dataData further reinforce ELVN-001's positioning...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
LH
LISTED
NYSE
Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs
News Preview
Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
GDRX
LISTED
NASDAQ
GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
News Preview
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy way to access lower prices on high-cost brand medications directly at the pharmacy counter.
“We are excited to partner with Giant Eagle to make bra...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
BAX
LISTED
NYSE
MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address Critical Nursing Challenges
News Preview
MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-quality and safe patient care already delivered at MUSC Health, MUSC’s health care system, through integrated connected care technologies.
This press release features multimedia. View th...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VNRX
LISTED
XASE
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
News Preview
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
NRSN
LISTED
NASDAQ
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
News Preview
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzhei...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VEEV
LISTED
NYSE
Veeva and BioMarin Form Long-Term Strategic Partnership
News Preview
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapiesPLEASANTON, Calif., and SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their long-standing relation...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
LH
LISTED
NYSE
NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
News Preview
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. Th...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VEEV
LISTED
NYSE
Veeva and BioMarin Form Long-Term Strategic Partnership
News Preview
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapiesPLEASANTON, Calif., and SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their long-standing relation...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
WGS
LISTED
NASDAQ
GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare intelligence. Through the partnership, GeneDx’s Infinity™ will leverage real-world patient insights from Komodo’s Healthcare Map®, to create the most compreh...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
TEM
LISTED
NASDAQ
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium. The meeting is being held on January 8–10 in San Francisco, California.
“The research Tempus is presenting at...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
VTYX
LISTED
NASDAQ
VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is fair to Ventyx shareholders.
Halper Sadeh encourages Ventyx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary H...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
SXTC
LISTED
NASDAQ
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
News Preview
TAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soak...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
COH
LISTED
ASX
Cochlear Announces Availability of Nucleus Nexa System to US Military Veterans
News Preview
LONE TREE, Colo., Jan. 8, 2026 /PRNewswire/ -- Cochlear, the global leader in implantable hearing solutions, is proud to announce that the groundbreaking Nucleus® Nexa® System is now available to eligible US military veterans at VA clinics nationwide....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
CLTX
LISTED
NASDAQ
Akari Therapeutics to Present at the 2026 Biotech Showcase
News Preview
In-person presentation on Tuesday, January 13th at 9:30 AM PT...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
GNLX
LISTED
NASDAQ
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
News Preview
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be s...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
PACB
LISTED
NASDAQ
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell
News Preview
Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
TNGX
LISTED
NASDAQ
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
News Preview
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the compan...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
GH
LISTED
NASDAQ
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military’s health insurance coverage, with no copay for average-risk individuals ages 45 and older.
Shiel...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
XNCR
LISTED
NASDAQ
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
News Preview
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates.
“Xencor designs proteins that enable potential...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
AADI
LISTED
NASDAQ
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
News Preview
Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ADC HWK-016, anticipated Phase 1 start this quarterInitial clinical data from both programs anticipated in early 2027MORRISTOWN, N.J., Jan. 8, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK),...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
HALO
LISTED
NASDAQ
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
News Preview
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumabSAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive license agreement with Takeda in December 2025. The agreement provides Takeda with acces...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
BGXX
LISTED
NASDAQ
Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys’ Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
News Preview
Court Found No Wrongdoing by Lynn Stockwell; Judgment Imposed Joint and Several Liability Due to Counsel’s Failure...
Themefolio
Profiler
Peergroup
© Newsfile
08.01.2026
BIOV
LISTED
CSE
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen deliver...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
SPRB
LISTED
OTC
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
News Preview
Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that, on January 7, 2026, it entered into a loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenu...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced positive results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
PSNL
LISTED
NASDAQ
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter Strategic and Operational Highlights
Secured Milestone Medicare Coverage: Received Medicare coverage...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
CRL
LISTED
NYSE
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that James C. (Jim) Foster, Chair, President, and Chief Executive Officer (CEO), plans to retire, effective on May 5, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders. The Company’s Board of Directors (Board) has unanimously appointed Birgit Girshick, curre...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
45520
LISTED
XJPX
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12–15, 2026.
Presentation Details
Date: Thursday, January 15, 2026
Time: 9:00...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
TRVI
LISTED
NASDAQ
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
News Preview
FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosisPhase 2b refractory chronic cough trial planned to initiate in the first half of 2026 NEW HAVEN, Conn., Jan. 8, 2026 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage bi...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
MDMA
LISTED
CSE
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
News Preview
PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
ALXO
LISTED
NASDAQ
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
News Preview
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
ARDX
LISTED
NASDAQ
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
News Preview
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
XLO
LISTED
NASDAQ
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
News Preview
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
ALLO
LISTED
NASDAQ
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today outlined 2026 as a program-defining year for allogeneic CAR T, with multiple first-half clini...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
ADCT
LISTED
NYSE
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
MNKD
LISTED
NASDAQ
MannKind Provides Business Updates and 2026 Growth Drivers
News Preview
MannKind Provides Business Updates and 2026 Growth Drivers...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
CRMD
LISTED
NASDAQ
CorMedix Therapeutics Announces Leadership and Board Updates
News Preview
BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Jo...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VEEV
LISTED
NYSE
Veeva Announces Environmental Monitoring Solution to Modernize Quality Control in Manufacturing
News Preview
Veeva's expanded manufacturing QC solutions to automate
environmental sample collection and analysis
BARCELONA, Spain, Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new environmental monitoring (EM) solution to advance quality control (QC) for manufacturing operations. Veeva Environmental Monitoring, a cloud...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Correction-Transaction in Own Shares
News Preview
The Company wishes to correct an error in the announcement released at 17:38 on
7 January 2026
regarding its transaction in own shares.
The number of Ordinary shares held in treasury following the purchase should have been stated as
214,334,345
(not 2...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VEEV
LISTED
NYSE
Veeva Announces Environmental Monitoring Solution to Modernize Quality Control in Manufacturing
News Preview
Veeva's expanded manufacturing QC solutions to automate environmental sample collection and analysisPLEASANTON, Calif., Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new environmental monitoring (EM) solution to advance quality control (QC) for manufacturing operations. Veeva Environmental Monitoring, a cloud-native app...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
CPRX
LISTED
NASDAQ
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
News Preview
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes'...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
